Abvacc, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Integrated Biotherapeutic Vaccines, Inc. (to 2022)
0
Ending by 2030
Feb 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 18, 2027The maintenance fee for Immunogenic Composition Comprising Alpha-Hemolysin Oligopeptides (US 9,109,036) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
- 2 fees due May 26 to 28, 2027 · next May 26
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,109,036 | Immunogenic Composition Comprising Alpha-Hemolysin Oligopeptides In force · High confidence | In force | High confidence | |
| US 10,023,848 | Immunogenic Composition Comprising Panton-Valentine Leukocidin (PVL) Derived Polypeptides In force · High confidence | In force | High confidence | |
| US 9,815,872 | Toxoid Peptides Derived from Phenol Soluble Modulin, Delta Toxin, Superantigens, and Fusions Thereof In force · High confidence | In force | High confidence | |
| US 10,174,085 | Toxoid Peptides Derived From Phenol Soluble Modulin, Delta Toxin, Superantigens, and Fusions Thereof In force · High confidence | In force | High confidence | |
| US 11,028,153 | Targeting Immunological Functions to the Site of Bacterial Infections Using Cell Wall Targeting Domains of Bacteriolysins In force · High confidence | In force | High confidence | |
| US 10,487,140 | Targeting Immunological Functions to the Site of Bacterial Infections Using Cell Wall Targeting Domains of Bacteriolysins In force · High confidence | In force | High confidence | |
| US 11,421,021 | Immunogenic Compositions Comprising Staphylococcus Aureus Leukocidin Luka and Lukb Derived Polypeptides In force · High confidence | In force | High confidence | |
| US 11,260,120 | Immunogenic Composition Comprising a Fusion Peptide Derived from Superantigen Toxoids In force · High confidence | In force | High confidence | |
| US 11,826,412 | Immunogenic Composition Comprising a Fusion Peptide Derived from Superantigen Toxoids In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.